Eyecelerator Teams up With Unither Pharmaceuticals and Ora for Web Series on Transforming Ophthalmic Innovation into Market-Ready Therapies

Eyecelerator Teams up With Unither Pharmaceuticals and Ora for Web Series on Transforming Ophthalmic Innovation into Market-Ready Therapies

SAN FRANCISCO - Eyecelerator®, in collaboration with Unither Pharmaceuticals and Ora, Inc., announces the launch of Eye to Market, a new web series dedicated to accelerating understanding of how ophthalmic innovations move from scientific insight to real-world adoption. The series brings together leaders across research, clinical development, manufacturing, and commercialization to unpack the challenges and opportunities shaping the future of eye care. Through expert interviews and real-world perspectives, Eye to Market highlights the steps required to bring breakthrough ophthalmic solutions to patients worldwide - from early-stage development through clinical validation, scale-up, regulatory strategy, and market access.

"Eye to Market was created to demystify the innovation pathway in ophthalmology," said Gil Kliman, MD, program director for Eyecelerator. "By opening the conversation across disciplines, we hope to help innovators and partners navigate complexity and ultimately deliver better outcomes for patients."

Unither Pharmaceuticals, a global contract development and manufacturing organization and the world leader in Blow-Fill-Seal sterile unit doses, contributes deep expertise in sterile manufacturing and drug delivery systems supporting ophthalmic innovation and accessibility. Ora, the world's leading full-service ophthalmic clinical research organization (CRO), brings decades of clinical development insight and a proven track record of advancing therapeutic and device innovation.

"Partnership and cross-functional collaboration are essential to transform promising ideas into approved, scalable treatments," said Brian Kenyon, business development manager, North America, for Unither Pharmaceuticals.

"From first-in-human studies through global commercialization, successful product development requires more than technical execution-it demands insight, experience, and empathy," said Ora Chief Scientific Officers George Ousler and Keith Lane. "This series highlights the power of rigorous science, collaboration, and a shared commitment to patients-bringing together industry-leading experts to illuminate the pathway from innovation to impact in ophthalmology."

About the Series

• <_o3a_p>Format: short expert-led episodes
• Audience: innovators, clinicians, investors, manufacturers, policymakers, and industry leaders
• Themes include: translational research, clinical development, patient-centric innovation, manufacturing and delivery platforms, regulatory and market entry, and global access
  Episodes will be published on the Eyecelerator YouTube channel and shared across partner channels.

About Eyecelerator®<_o3a_p>

Eyecelerator, a partner of the American Academy of Ophthalmology, advances eye care innovation by connecting mission-driven entrepreneurs, investors, physicians, and business leaders through next-generation business conferences. For more information, visit www.eyecelerator.com <_o3a_p>

About Unither Pharmaceuticals<_o3a_p>

Unither Pharmaceuticals is a global contract development and manufacturing organization specializing in ophthalmic liquid formulations in unit-dose and multi-dose formats. For more than 30 years, we have partnered with innovative pharmaceutical companies to support the development and industrialization of health solutions for U.S. and global markets. As a world leader in Blow-Fill-Seal (BFS) technology, we offer large-scale manufacturing capabilities with an annual production capacity of 5 billion unit doses. Unither operates a global manufacturing network across the United States, South America, Europe and Asia, with products distributed in more than 100 countries. For more information, please visit www.unither-pharma.com <_o3a_p>

About Ora<_o3a_p>

Ora is the world's leading full-service ophthalmic drug and device CRO with employees in over 20 countries around the world. For over 50 years, we have proudly helped our clients earn more than 90 ophthalmic product approvals. We support a wide array of innovators and organizations, from startups to global pharmaceutical and device companies, to efficiently bring new products from concept to market. Ora's unique methodologies, clinical models, and regulatory strategies have been refined and proven across thousands of global projects. For more information, please visit www.oraclinical.com <_o3a_p>